BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22825691)

  • 21. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
    Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
    Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Homesley HD; Filiaci V; Markman M; Bitterman P; Eaton L; Kilgore LC; Monk BJ; Ueland FR;
    J Clin Oncol; 2007 Feb; 25(5):526-31. PubMed ID: 17290061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
    Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
    Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
    Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma.
    Lacour RA; Euscher E; Atkinson EN; Sun CC; Ramirez PT; Coleman RL; Brown J; Gano JB; Burke TW; Ramondetta LM
    Int J Gynecol Cancer; 2011 Apr; 21(3):517-22. PubMed ID: 21436700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.
    Hoskins PJ; Le N; Ellard S; Lee U; Martin LA; Swenerton KD; Tinker AV;
    Gynecol Oncol; 2008 Jan; 108(1):58-62. PubMed ID: 17935761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Combination chemotherapy with carboplatin and weekly Paclitaxel in patients with advanced non-small cell lung cancer].
    Hashizume T; Ogura T; Kozawa S; Yamaguchi N; Hayashi M; Nakamura M; Miyazawa N; Watanuki Y; Takahashi H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):471-5. PubMed ID: 16612156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
    Powell MA; Filiaci VL; Rose PG; Mannel RS; Hanjani P; Degeest K; Miller BE; Susumu N; Ueland FR
    J Clin Oncol; 2010 Jun; 28(16):2727-31. PubMed ID: 20421537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
    Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
    BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
    Shea T; Graham M; Bernard S; Steagall A; Wiley J; Serody J; Brecher M; Bentley S; Johnston C; Vaisman A
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):80-5. PubMed ID: 7481867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.
    Downs LS; Chura JC; Argenta PA; Judson PL; Ghebre R; Geller MA; Carson LF
    Gynecol Oncol; 2011 Feb; 120(2):265-9. PubMed ID: 21145100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
    Kosmidis P; Mylonakis N; Fountzilas G; Samantas E; Athanasiadis A; Skarlos D
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):68-70. PubMed ID: 9007126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.